{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:48:06Z","timestamp":1787316486496,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Mycoplasma genitalium<\/jats:italic>\n                      (MG) is an emerging sexually transmitted infection, often harboring resistance-associated mutations to azithromycin (AZM). Global surveillance has been mandated to tackle the burden caused by MG, yet no data are available for Austria. Thus, we aimed to investigate the prevalence of MG, disease characteristics, and treatment outcomes at the largest Austrian HIV\u2014and STI clinic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All MG test results at the Medical University of Vienna from 02\/2019 to 03\/2022 were evaluated. Azithromycin resistance testing was implemented in 03\/2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 2671 MG tests, 199 distinct and mostly asymptomatic (68%; 135\/199) MG infections were identified, affecting 10% (178\/1775) of all individuals. This study included 83% (1479\/1775) men, 53% (940\/1775) men who have sex with men (MSM), 31% (540\/1754) HIV+, and 15% (267\/1775) who were using HIV pre-exposure prophylaxis (PrEP). In logistic regression analysis, \u2018MSM\u2019 (aOR 2.55 (95% CI 1.65\u20133.92)), \u2018use of PrEP\u2019 (aOR 2.29 (95% CI 1.58\u20133.32)), and \u2018history of syphilis\u2019 (aOR 1.57 (95% CI 1.01\u20132.24) were independent predictors for MG infections. Eighty-nine percent (178\/199) received treatment: 11% (21\/178) doxycycline (2\u00a0weeks), 52% (92\/178) AZM (5\u00a0days), and 37% ( 65\/178) moxifloxacin (7\u201310\u00a0days) and 60% (106\/178) had follow-up data available showing negative tests in 63% (5\/8), 76% (44\/58) and 85% (34\/40), respectively. AZM resistance analysis was available for 57% (114\/199)) and detected in 68% (78\/114). Resistance-guided therapy achieved a cure in 87% (53\/61), yet, empiric AZM-treatment (prior to 03\/2021) cleared 68% (26\/38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Mycoplasma genitalium<\/jats:italic>\n                      was readily detected in this Austrian observational study, affected predominantly MSM and often presented as asymptomatic disease. We observed a worryingly high prevalence of AZM resistance mutations; however, empiric AZM treatment cleared twice as many MG infections as expected.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-024-02261-6","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:01:47Z","timestamp":1713790907000},"page":"1921-1930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-8258","authenticated-orcid":false,"given":"David","family":"Chromy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Starossek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Grabmeier-Pfistershammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Adamek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Maischack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sammet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Sadoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Stary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Willinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Makristathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Michael","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"2261_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1128\/cmr.00006-11","volume":"24","author":"D Taylor-Robinson","year":"2011","unstructured":"Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev. 2011;24:498\u2013514. https:\/\/doi.org\/10.1128\/cmr.00006-11.","journal-title":"Clin Microbiol Rev"},{"key":"2261_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3201\/eid2504.181258","volume":"25","author":"TRH Read","year":"2019","unstructured":"Read TRH, Murray GL, Danielewski JA, Fairley CK, Doyle M, Worthington K, et al. Symptoms, Sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis. 2019;25:719\u201327. https:\/\/doi.org\/10.3201\/eid2504.181258.","journal-title":"Emerg Infect Dis"},{"key":"2261_CR3","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/olq.0000000000000793","volume":"45","author":"JJ Ong","year":"2018","unstructured":"Ong JJ, Aung E, Read TRH, Fairley CK, Garland SM, Murray G, et al. Clinical characteristics of anorectal Mycoplasma genitalium infection and microbial cure in men who have sex with men. Sex Transm Dis. 2018;45:522\u20136. https:\/\/doi.org\/10.1097\/olq.0000000000000793.","journal-title":"Sex Transm Dis"},{"key":"2261_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jgar.2019.06.015","volume":"18","author":"R Dumke","year":"2019","unstructured":"Dumke R, Ziegler T, Abbasi-Boroudjeni N, Rust M, Glaunsinger T. Prevalence of macrolide- and fluoroquinolone-resistant Mycoplasma genitalium strains in clinical specimens from men who have sex with men of two sexually transmitted infection practices in Berlin, Germany. J Glob Antimicrob Resist. 2019;18:118\u201321. https:\/\/doi.org\/10.1016\/j.jgar.2019.06.015.","journal-title":"J Glob Antimicrob Resist"},{"key":"2261_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/s1473-3099(20)30154-7","volume":"20","author":"DA Machalek","year":"2020","unstructured":"Machalek DA, Tao Y, Shilling H, Jensen JS, Unemo M, Murray G, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis. 2020;20:1302\u201314. https:\/\/doi.org\/10.1016\/s1473-3099(20)30154-7.","journal-title":"Lancet Infect Dis"},{"key":"2261_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1136\/sti.2006.022970","volume":"83","author":"B Andersen","year":"2007","unstructured":"Andersen B, Sokolowski I, \u00d8stergaard L, Kj\u00f8lseth M\u00f8ller J, Olesen F, Jensen JS. Mycoplasma genitalium: prevalence and behavioural risk factors in the general population. Sex Transm Infect. 2007;83:237\u201341. https:\/\/doi.org\/10.1136\/sti.2006.022970.","journal-title":"Sex Transm Infect"},{"key":"2261_CR7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1086\/656739","volume":"51","author":"P Oakeshott","year":"2010","unstructured":"Oakeshott P, Aghaizu A, Hay P, Reid F, Kerry S, Atherton H, et al. Is Mycoplasma genitalium in women the \u201cNew Chlamydia?\u201d A community-based prospective cohort study. Clin Infect Dis. 2010;51:1160\u20136. https:\/\/doi.org\/10.1086\/656739.","journal-title":"Clin Infect Dis"},{"key":"2261_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/cid\/cit752","volume":"58","author":"MJ Pond","year":"2014","unstructured":"Pond MJ, Nori AV, Witney AA, Lopeman RC, Butcher PD, Sadiq ST. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631\u20137. https:\/\/doi.org\/10.1093\/cid\/cit752.","journal-title":"Clin Infect Dis"},{"key":"2261_CR9","doi-asserted-by":"publisher","first-page":"e1917134","DOI":"10.1001\/jamanetworkopen.2019.17134","volume":"2","author":"JJ Ong","year":"2019","unstructured":"Ong JJ, Baggaley RC, Wi TE, Tucker JD, Fu H, Smith MK, et al. Global epidemiologic characteristics of sexually transmitted infections among individuals using preexposure prophylaxis for the prevention of HIV infection: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1917134. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.17134.","journal-title":"JAMA Netw Open"},{"key":"2261_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/sextrans-2019-054356","volume":"97","author":"CE Broad","year":"2021","unstructured":"Broad CE, Furegato M, Harrison MA, Pond MJ, Tan N, Okala S, et al. High prevalence of coinfection of azithromycin-resistant Mycoplasma genitalium with other STIs: a prospective observational study of London-based symptomatic and STI-contact clinic attendees. Sex Transm Infect. 2021;97:63\u20138. https:\/\/doi.org\/10.1136\/sextrans-2019-054356.","journal-title":"Sex Transm Infect"},{"key":"2261_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12879-020-4831-4","volume":"20","author":"K Jansen","year":"2020","unstructured":"Jansen K, Steffen G, Potthoff A, Schuppe AK, Beer D, Jessen H, et al. STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany. BMC Infect Dis. 2020;20:110. https:\/\/doi.org\/10.1186\/s12879-020-4831-4.","journal-title":"BMC Infect Dis"},{"key":"2261_CR12","doi-asserted-by":"publisher","first-page":"ofac217","DOI":"10.1093\/ofid\/ofac217","volume":"9","author":"A Ring","year":"2022","unstructured":"Ring A, Balakrishna S, Imkamp F, Burkard S, Triet F, Brunschweiler F, et al. High rates of asymptomatic Mycoplasma genitalium infections with high proportion of genotypic resistance to first-line macrolide treatment among men who have sex with men enrolled in the Zurich Primary HIV Infection Study. Open Forum Infect Dis. 2022;9:ofac217. https:\/\/doi.org\/10.1093\/ofid\/ofac217.","journal-title":"Open Forum Infect Dis"},{"key":"2261_CR13","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1093\/jac\/dkac281","volume":"77","author":"R Pitt","year":"2022","unstructured":"Pitt R, Boampong D, Day M, Jensen JS, Cole M. Challenges of in vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium. J Antimicrob Chemother. 2022;77:2901\u20137. https:\/\/doi.org\/10.1093\/jac\/dkac281.","journal-title":"J Antimicrob Chemother"},{"key":"2261_CR14","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","volume":"36","author":"JS Jensen","year":"2022","unstructured":"Jensen JS, Cusini M, Gomberg M, Moi H, Wilson J, Unemo M. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36:641\u201350. https:\/\/doi.org\/10.1111\/jdv.17972.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2261_CR15","doi-asserted-by":"publisher","first-page":"ofaa291","DOI":"10.1093\/ofid\/ofaa291","volume":"7","author":"M Doyle","year":"2020","unstructured":"Doyle M, Vodstrcil LA, Plummer EL, Aguirre I, Fairley CK, Bradshaw CS. nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance. Open Forum Infect Dis. 2020;7:ofaa291. https:\/\/doi.org\/10.1093\/ofid\/ofaa291.","journal-title":"Open Forum Infect Dis"},{"key":"2261_CR16","doi-asserted-by":"publisher","first-page":"e2127","DOI":"10.1093\/cid\/ciaa1832","volume":"73","author":"B Ber\u00e7ot","year":"2020","unstructured":"Ber\u00e7ot B, Charreau I, Clotilde R, Delaugerre C, Chidiac C, Pialoux G, et al. High prevalence and high rate of antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men. A sub-study of the ANRS ipergay PrEP trial. Clin Infect Dis. 2020;73:e2127\u201333. https:\/\/doi.org\/10.1093\/cid\/ciaa1832.","journal-title":"Clin Infect Dis"},{"key":"2261_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/sextrans-2019-054335","volume":"96","author":"JT Van Praet","year":"2020","unstructured":"Van Praet JT, Steyaert S, Vandecasteele S, Van Den Bergh B, Mahieu H, De Buyser S, et al. Mycoplasma genitalium acquisition and macrolide resistance after initiation of HIV pre-exposure prophylaxis in men who have sex with men. Sex Transm Infect. 2020;96:396\u20138. https:\/\/doi.org\/10.1136\/sextrans-2019-054335.","journal-title":"Sex Transm Infect"},{"key":"2261_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/09564624211070704","volume":"33","author":"I De Baetselier","year":"2022","unstructured":"De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, et al. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections. Int J STD AIDS. 2022;33:385\u201390. https:\/\/doi.org\/10.1177\/09564624211070704.","journal-title":"Int J STD AIDS"},{"key":"2261_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jiph.2022.07.012","volume":"15","author":"P Ahaus","year":"2022","unstructured":"Ahaus P, Schmidt AJ, Skaletz-Rorowski A, Uhrmacher M, Serova K, Kayser A, et al. Changes in the user profiles of HIV pre-exposure prophylaxis (PrEP) before and after PrEP reimbursement. J Infect Public Health. 2022;15:955\u201360. https:\/\/doi.org\/10.1016\/j.jiph.2022.07.012.","journal-title":"J Infect Public Health"},{"key":"2261_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70:1\u2013187. https:\/\/doi.org\/10.15585\/mmwr.rr7004a1.","journal-title":"MMWR Recomm Rep"},{"key":"2261_CR21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1177\/0956462419825948","volume":"30","author":"S Soni","year":"2019","unstructured":"Soni S, Horner P, Rayment M, Pinto-Sander N, Naous N, Parkhouse A, et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018). Int J STD AIDS. 2019;30:938\u201350. https:\/\/doi.org\/10.1177\/0956462419825948.","journal-title":"Int J STD AIDS"},{"key":"2261_CR22","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/jdv.13849","volume":"30","author":"JS Jensen","year":"2016","unstructured":"Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30:1650\u20136. https:\/\/doi.org\/10.1111\/jdv.13849.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2261_CR23","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/sextrans-2019-054124","volume":"96","author":"M Fern\u00e1ndez-Huerta","year":"2020","unstructured":"Fern\u00e1ndez-Huerta M, Barber\u00e1 MJ, Esperalba J, Fernandez-Naval C, Vall-Mayans M, Arando M, et al. Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sex Transm Infect. 2020;96:300\u20135. https:\/\/doi.org\/10.1136\/sextrans-2019-054124.","journal-title":"Sex Transm Infect"},{"key":"2261_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/sextrans-2019-054310","volume":"96","author":"RL Latimer","year":"2020","unstructured":"Latimer RL, Shilling HS, Vodstrcil LA, Machalek DA, Fairley CK, Chow EPF, et al. Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: a systematic review and meta-analysis. Sex Transm Infect. 2020;96:563\u201370. https:\/\/doi.org\/10.1136\/sextrans-2019-054310.","journal-title":"Sex Transm Infect"},{"key":"2261_CR25","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/cid\/cix439","volume":"65","author":"SM Jenness","year":"2017","unstructured":"Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65:712\u20138. https:\/\/doi.org\/10.1093\/cid\/cix439.","journal-title":"Clin Infect Dis"},{"key":"2261_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1017\/s0950268818000092","volume":"146","author":"J Buyze","year":"2018","unstructured":"Buyze J, Vanden Berghe W, Hens N, Kenyon C. Current levels of gonorrhoea screening in MSM in Belgium may have little effect on prevalence: a modelling study. Epidemiol Infect. 2018;146:333\u20138. https:\/\/doi.org\/10.1017\/s0950268818000092.","journal-title":"Epidemiol Infect"},{"key":"2261_CR27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/olq.0000000000000824","volume":"45","author":"A Tsoumanis","year":"2018","unstructured":"Tsoumanis A, Hens N, Kenyon CR. Is screening for chlamydia and gonorrhea in men who have sex with men associated with reduction of the prevalence of these infections? A systematic review of observational studies. Sex Transm Dis. 2018;45:615\u201322. https:\/\/doi.org\/10.1097\/olq.0000000000000824.","journal-title":"Sex Transm Dis"},{"key":"2261_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/qad.0000000000002020","volume":"33","author":"C Kenyon","year":"2019","unstructured":"Kenyon C. We need to consider collateral damage to resistomes when we decide how frequently to screen for chlamydia\/gonorrhoea in preexposure prophylaxis cohorts. AIDS. 2019;33:155\u20137. https:\/\/doi.org\/10.1097\/qad.0000000000002020.","journal-title":"AIDS"},{"key":"2261_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2334-14-13","volume":"14","author":"BG Bell","year":"2014","unstructured":"Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13. https:\/\/doi.org\/10.1186\/1471-2334-14-13.","journal-title":"BMC Infect Dis"},{"key":"2261_CR30","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/cid\/ciu1162","volume":"60","author":"M Bissessor","year":"2015","unstructured":"Bissessor M, Tabrizi SN, Twin J, Abdo H, Fairley CK, Chen MY, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60:1228\u201336. https:\/\/doi.org\/10.1093\/cid\/ciu1162.","journal-title":"Clin Infect Dis"},{"key":"2261_CR31","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3201\/eid2402.170902","volume":"24","author":"TRH Read","year":"2018","unstructured":"Read TRH, Jensen JS, Fairley CK, Grant M, Danielewski JA, Su J, et al. Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection. Emerg Infect Dis. 2018;24:328\u201335. https:\/\/doi.org\/10.3201\/eid2402.170902.","journal-title":"Emerg Infect Dis"},{"key":"2261_CR32","volume-title":"Gonococcal antimicrobial susceptibility surveillance in the EU\/EEA: summary of results for 2019","author":"European Center for Disease Control and Prevention","year":"2021","unstructured":"European Center for Disease Control and Prevention. Gonococcal antimicrobial susceptibility surveillance in the EU\/EEA: summary of results for 2019. Stockholm: ECDC; 2021."},{"key":"2261_CR33","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1093\/cid\/ciz050","volume":"69","author":"N Dukers-Muijrers","year":"2019","unstructured":"Dukers-Muijrers N, Wolffs PFG, De Vries H, G\u00f6tz HM, Heijman T, Bruisten S, et al. Treatment effectiveness of azithromycin and doxycycline in uncomplicated rectal and vaginal chlamydia trachomatis infections in women: a multicenter observational study (FemCure). Clin Infect Dis. 2019;69:1946\u201354. https:\/\/doi.org\/10.1093\/cid\/ciz050.","journal-title":"Clin Infect Dis"},{"key":"2261_CR34","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1056\/NEJMoa2031631","volume":"384","author":"A Lau","year":"2021","unstructured":"Lau A, Kong FYS, Fairley CK, Templeton DJ, Amin J, Phillips S, et al. Azithromycin or doxycycline for asymptomatic rectal Chlamydia trachomatis. N Engl J Med. 2021;384:2418\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2031631.","journal-title":"N Engl J Med"},{"key":"2261_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420949126","author":"M Unemo","year":"2020","unstructured":"Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020. https:\/\/doi.org\/10.1177\/0956462420949126.","journal-title":"Int J STD AIDS"},{"key":"2261_CR36","doi-asserted-by":"publisher","first-page":"106656","DOI":"10.1016\/j.ijantimicag.2022.106656","volume":"60","author":"A Geusau","year":"2022","unstructured":"Geusau A, Chromy D, Heissenberger D, Lippert K, Eder C, Heger F, et al. Resistance profiles of Neisseria gonorrhoeae isolates in Vienna, Austria: a phenotypic and genetic characterization from 2013 to 2020. Int J Antimicrob Agents. 2022;60: 106656. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106656.","journal-title":"Int J Antimicrob Agents"},{"key":"2261_CR37","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1086\/593188","volume":"47","author":"JS Jensen","year":"2008","unstructured":"Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546\u201353. https:\/\/doi.org\/10.1086\/593188.","journal-title":"Clin Infect Dis"},{"key":"2261_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/sextrans-2020-054511","volume":"97","author":"I De Baetselier","year":"2020","unstructured":"De Baetselier I, Kenyon C, Vanden Berghe W, Smet H, Wouters K, Van den Bossche D, et al. An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018. Sex Transm Infect. 2020;97:297\u2013303. https:\/\/doi.org\/10.1136\/sextrans-2020-054511.","journal-title":"Sex Transm Infect"},{"key":"2261_CR39","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1093\/jac\/dkv136","volume":"70","author":"RH Nijhuis","year":"2015","unstructured":"Nijhuis RH, Severs TT, Van der Vegt DS, Van Zwet AA, Kusters JG. High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment. J Antimicrob Chemother. 2015;70:2515\u20138. https:\/\/doi.org\/10.1093\/jac\/dkv136.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02261-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02261-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02261-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:08:54Z","timestamp":1729667334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02261-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02261-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DC served as a speaker and\/or advisory board member for Gilead, ViiV Healthcare, and MSD and received travel support from MSD, ViiV Healthcare, and Gilead. LS has nothing to disclose. KGP served as a speaker and\/or consultant and\/or advisory board member for ViiV Healthcare and Gilead and received travel support from ViiV Healthcare and Gilead. SA has nothing to disclose. FM has nothing to disclose. SS served as advisory board member for MSD and received travel support from Gilead. BS received industry grants\/royalties from Abbott\/AbbVie, Almirall, Celgene, Eli Lilly, Galderma, Novartis, Pfizer, Trevi Therapeutics, UCB, Janssen Cilag. GS has nothing to disclose. BW served as a speaker for Gilead and advisory board member for MSD. WW served as a speaker, consultant, and\/or advisory board member for LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. SE served as a speaker and\/or advisory board member for Gilead, GSK, Janssen, MSD, ViiV Healthcare, and MSD and received travel support from Gilead, Janssen, MSD, and ViiV Healthcare and research grant from Gilead, Janssen, MSD, and ViiV Healthcare. AM has nothing to disclose. WMB served as a speaker and\/or consultant and\/or advisory board member for AbbVie, ViiV Healthcare, and Takeda and received travel support from AbbVie, MSD, ViiV Healthcare, and Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}